Tokyo, Japan, February 8, 2013 - Otsuka Pharmaceutical Co., Ltd. today announced that Samsca^® (tolvaptan), vasopressin V2 receptor antagonist indicated for the treatment of volume overload in patients with heart failure, was granted additional approval of tablets in 7.5mg dosage on February 4, 2013.